SKYE Earnings — Skye Bioscience, Inc. Common Stock Post-ER Performance | BigEarnings
SKYE — Skye Bioscience, Inc. Common Stock
XNAS · Healthcare · Biotechnology
Price$0.71
Market Cap$26.7M
P/E—
52W Range$0.57 – $5.75
Next Earnings2026-08-06
About Skye Bioscience, Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
